HRT Financial’s Apimeds Pharmaceuticals US APUS Stock Holding History

HRT Financial’s Portfolio APUS Stock Details APUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,357	Closed	-$24K	–	4318
2025 Q3	$24K	Buy	+1,357	New	+$25.1K	﹤0.01%	2688

Other funds holding APUS

HTHT

Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

HRT Financial's APUS Position: Q4 2025 in Review

HRT Financial sold out of Apimeds Pharmaceuticals US (APUS) in Q4 2025, closing a stake of 1,357 shares — an estimated $24K sold.

HRT Financial first reported a position in APUS in Q3 2025 and held it in 1 quarter. The position peaked at $24K in Q3 2025. 7 funds tracked by Wall St. Rank hold APUS as of Q4 2025.

HRT Financial reported no remaining Apimeds Pharmaceuticals US position as of Q4 2025 after selling out during the quarter.
HRT Financial sold 1,357 Apimeds Pharmaceuticals US shares in Q4 2025, an estimated $24K.
HRT Financial first reported a position in Apimeds Pharmaceuticals US in Q3 2025 and held it in 1 quarter.
HRT Financial's Apimeds Pharmaceuticals US position peaked at $24K in Q3 2025.
7 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.